AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38098022 — intervention group
Group type: EXPERIMENTAL
Intervention: S. persica toothbrush (MTB)
Number of subjects: 78
Study 38098022 — intervention group
Group type: COMPARATOR
Intervention: Standard toothbrush (STB)
Number of subjects: 78
Study 38098022 — intervention group
Group type: COMPARATOR
Intervention: All groups (MCS, MTB, STB)
Number of subjects: 78
Study 38098024 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated TKA
Number of subjects: 76
Study 38098024 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 76
Study 38098024 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated TKA in allergy patients
Number of subjects: 76
Study 38098024 — intervention group
Group type: COMPARATOR
Intervention: Matched-pair group receiving coated implant
Number of subjects: 76
Study 38098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban interruption in major surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban interruption in nonmajor surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural-only interruption in major surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: COMPARATOR
Intervention: Preprocedural-only interruption in nonmajor surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural-only interruption in major surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: COMPARATOR
Intervention: Postprocedural-only interruption in nonmajor surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding rates in major surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: COMPARATOR
Intervention: Bleeding rates in nonmajor surgeries
Number of subjects: 788
Study 38098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event rates for bleeding and thromboembolic events
Number of subjects: 788
Study 38098080 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 1553
Study 38098080 — intervention group
Group type: COMPARATOR
Intervention: Non-obstructive sleep apnea (non-OSA)
Number of subjects: 1553
Study 38098079 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged leadership strategies
Number of subjects: 39
Study 38098079 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership involvement and mentorship during the intervention
Number of subjects: 39
Study 38098079 — intervention group
Group type: EXPERIMENTAL
Intervention: Training prioritizing leadership visibility and open communication
Number of subjects: 39
Study 38098145 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCS + more widely meshed STSG
Number of subjects: 65
Study 38098145 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care meshed STSG (control)
Number of subjects: 65
Study 38098145 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCS + more widely meshed STSG and Standard-of-care meshed STSG (control)
Number of subjects: 65
Study 38098221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg/day for 3 days and 200 mg/day for 11 days
Number of subjects: 116
Study 38098221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 38098221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 116
Study 38098261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 68
Study 38098261 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 68
Study 38098635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble program
Number of subjects: 149
Study 38098635 — intervention group
Group type: COMPARATOR
Intervention: SAU (support as usual)
Number of subjects: 149
Study 38098734 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Therapy for Obesity App (DTxO)
Number of subjects: 0
Study 38098734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 38098848 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct epiglottis lifting
Number of subjects: 129
Study 38098848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperangulated videolaryngoscopy
Number of subjects: 129
Study 38098848 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct epiglottis lifting with hyperangulated videolaryngoscope
Number of subjects: 129
Study 38098848 — intervention group
Group type: COMPARATOR
Intervention: Macintosh videolaryngoscopy
Number of subjects: 129
Study 38099081 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated high-dose theta burst stimulation (ahTBS)
Number of subjects: 45
Study 38099081 — intervention group
Group type: COMPARATOR
Intervention: 1-Hz repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 45
Study 38099334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 0
Study 38099334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38099506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 1187
Study 38099506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study 38099673 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG171 (150-900 mg single ascending doses)
Number of subjects: 78
Study 38099673 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG171 (150 and 300 mg multiple ascending doses)
Number of subjects: 78
Study 38099673 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG171/ritonavir (150/100 mg BID for 5 days)
Number of subjects: 78
Study 38099673 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG171/ritonavir (150/100 mg BID)
Number of subjects: 78
Study 38099732 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPECT model predicting post-ICU health problems at 3 months
Number of subjects: 2476
Study 38099912 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL
Number of subjects: 180
Study 38099912 — intervention group
Group type: COMPARATOR
Intervention: MitraClip
Number of subjects: 180
Study 38099912 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller flail gap
Number of subjects: 180
Study 38099944 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2565
Study 38099944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2565
Study 38100078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol Sodium Ophthalmic Solution, dosage and duration not available
Number of subjects: 0
Study 38100098 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38100110 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose, biannual administration over 2 years)
Number of subjects: 76092
Study 38100110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, biannual administration over 2 years)
Number of subjects: 76092
Study 38100172 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program including face-to-face counseling on lifestyle modifications, blood pressure monitoring, and medication compliance-related health education during enrollment and monthly follow-ups.
Number of subjects: 432
Study 38100172 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 432
Study 38100172 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the hospital
Number of subjects: 432
Study 38100226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 70
Study 38100226 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 70
Study 38100451 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias con Orgullo
Number of subjects: 306
Study 38100451 — intervention group
Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 306
Study 38100536 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia virus expressing Nipah virus glycoprotein (G)
Number of subjects: 0
Study 38100536 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia virus expressing Nipah virus fusion (F) protein
Number of subjects: 0
Study 38100536 — intervention group
Group type: COMPARATOR
Intervention: Other vaccinia virus vectors (control group)
Number of subjects: 0
Study 38100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg subcutaneously every four weeks
Number of subjects: 118
Study 38100820 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 150
Study 38100820 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference
Number of subjects: 150
Study 38100820 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 150
Study 38100820 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery
Number of subjects: 150
Study 38100820 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip
Number of subjects: 150
Study 38101205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 20
Study 38101205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 20
Study 38101250 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPPI (Homebound Elderly People Psychotherapeutic Intervention)
Number of subjects: 199
Study 38101250 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 199
Study 38101301 — intervention group
Group type: EXPERIMENTAL
Intervention: AADvac1 (active immunotherapy against pathological tau protein)
Number of subjects: 119
Study 38101315 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 116
Study 38101315 — intervention group
Group type: COMPARATOR
Intervention: Before surgery
Number of subjects: 116
Study 38101315 — intervention group
Group type: EXPERIMENTAL
Intervention: One year after laparoscopic sleeve gastrectomy
Number of subjects: 116
Study 38101315 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 116
Study 38101431 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy (1200 mg IV every 3 weeks)
Number of subjects: 1213
Study 38101431 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy
Number of subjects: 1213
Study 38101431 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 1213
Study 38101433 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus platinum-based chemotherapy (group A)
Number of subjects: 1213
Study 38101433 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (group C)
Number of subjects: 1213
Study 38101437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunvozertinib 300 mg once daily until meeting discontinuation criteria
Number of subjects: 104
Study 38101437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunvozertinib 300 mg once daily
Number of subjects: 104
Study 38101429 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically confirmed diagnosis of familial hypercholesterolaemia
Number of subjects: 11848
Study 38101429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of familial hypercholesterolaemia
Number of subjects: 11848
Study 38101429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering medication (LLM) usage
Number of subjects: 11848
Study 38101429 — intervention group
Group type: COMPARATOR
Intervention: Genetic diagnosis vs. clinical criteria
Number of subjects: 11848
Study 38101429 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial-hypercholesterolaemia-related physical signs and cardiovascular risk factors
Number of subjects: 11848
Study 38101517 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention
Number of subjects: 81
Study 38101756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus prednisolone
Number of subjects: 70
Study 38101756 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine plus prednisolone
Number of subjects: 70
Study 38101824 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day intensive cognitive behavioural therapy (B4DT)
Number of subjects: 120
Study 38101824 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive behavioural therapy (standard CBT)
Number of subjects: 120
Study 38101830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using Papacárie Duo
Number of subjects: 3
Study 38101830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using 5% sodium hypochlorite solution
Number of subjects: 3
Study 38101830 — intervention group
Group type: COMPARATOR
Intervention: Selective removal of carious dentinal tissue using a curette (Control group)
Number of subjects: 3
Study 38101840 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium binders (PB) treatment for hyperkalaemia (HK)
Number of subjects: 350
Study 38101840 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of serum potassium (S-K)
Number of subjects: 350
Study 38101846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasound (BUS) for monitoring inflammation
Number of subjects: 50
Study 38101846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasound (BUS)
Number of subjects: 50
Study 38101850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) programme
Number of subjects: 81
Study 38101850 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 81
Study 38101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) administered at primary motor cortex
Number of subjects: 88
Study 38101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) administered at primary sensory cortex
Number of subjects: 88
Study 38101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) administered at dorsolateral prefrontal cortex
Number of subjects: 88
Study 38101851 — intervention group
Group type: COMPARATOR
Intervention: Sham control group
Number of subjects: 88
Study 38101860 — intervention group
Group type: EXPERIMENTAL
Intervention: pTVG-HP (100 µg administered intradermally) and nivolumab (240 mg intravenous infusion) every 2 weeks for 3 months, then every 4 weeks for 1 year.
Number of subjects: 19
Study 38101860 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 38101861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Ty21a
Number of subjects: 25
Study 38101861 — intervention group
Group type: COMPARATOR
Intervention: Standard BCG
Number of subjects: 25
Study 38101901 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg NLY01
Number of subjects: 255
Study 38101901 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg NLY01
Number of subjects: 255
Study 38101901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 38101904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerliponase alfa (300 mg) administered via intracerebroventricular infusion every 2 weeks for a mean of 272.1 weeks.
Number of subjects: 24
Study 38101904 — intervention group
Group type: COMPARATOR
Intervention: Historical controls with untreated CLN2 disease from the DEM-CHILD database.
Number of subjects: 24
Study 38101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 25 mg once daily
Number of subjects: 2366
Study 38101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 25 mg twice daily
Number of subjects: 2366
Study 38101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 50 mg twice daily
Number of subjects: 2366
Study 38101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 100 mg twice daily
Number of subjects: 2366
Study 38101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 200 mg twice daily
Number of subjects: 2366
Study 38101902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2366
Study 38101918 — intervention group
Group type: EXPERIMENTAL
Intervention: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Number of subjects: 119
Study 38101918 — intervention group
Group type: EXPERIMENTAL
Intervention: BASDAI individual items
Number of subjects: 119
Study 38101918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome scores
Number of subjects: 119
Study 38101923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair placement (≤3 feet (0.9 m) of patient's bedside and facing the bed)
Number of subjects: 125
Study 38101923 — intervention group
Group type: COMPARATOR
Intervention: Usual chair location (control)
Number of subjects: 125
Study 38101923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair placement
Number of subjects: 125
Study 38101984 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 45
Study 38102013 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient genicular artery embolization (GAE) using an ethiodized oil-based emulsion (mixture of ioversol and ethiodized oil in a 1:3 ratio)
Number of subjects: 22
Study 38102013 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient genicular artery embolization (GAE) using an ethiodized oil-based emulsion
Number of subjects: 22
Study 38102152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic feeding
Number of subjects: 29
Study 38102152 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral feeding (Control)
Number of subjects: 29
Study 38102226 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/d
Number of subjects: 42
Study 38102448 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day antimicrobial therapy
Number of subjects: 0
Study 38102448 — intervention group
Group type: COMPARATOR
Intervention: 14-day antimicrobial therapy
Number of subjects: 0
Study 38102496 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT (cognitive behavioral therapy)
Number of subjects: 44
Study 38102496 — intervention group
Group type: COMPARATOR
Intervention: AC (attention control)
Number of subjects: 44
Study 38102527 — intervention group
Group type: EXPERIMENTAL
Intervention: One change to childbirth plan
Number of subjects: 3532
Study 38102527 — intervention group
Group type: EXPERIMENTAL
Intervention: Two changes to childbirth plan
Number of subjects: 3532
Study 38102527 — intervention group
Group type: EXPERIMENTAL
Intervention: One change in childbirth plan (primigravida)
Number of subjects: 3532
Study 38102530 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders (received if the PCD had not been used for 2 consecutive days)
Number of subjects: 29
Study 38102530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 29
Study 38102530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pooled population)
Number of subjects: 29
Study 38102530 — intervention group
Group type: EXPERIMENTAL
Intervention: Full compliance (both groups)
Number of subjects: 29
Study 38102535 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 193
Study 38102535 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 193
Study 38102536 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised endurance group (SEG, n=30)
Number of subjects: 120
Study 38102536 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised strength group (SSG, n=30)
Number of subjects: 120
Study 38102536 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised concurrent group (SCG, n=30)
Number of subjects: 120
Study 38102536 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=30)
Number of subjects: 120
Study 38102544 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' medication reconciliation
Number of subjects: 161
Study 38102544 — intervention group
Group type: COMPARATOR
Intervention: Emergency physicians' medication reconciliation
Number of subjects: 161
Study 38102544 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' written copy of drug history
Number of subjects: 161
Study 38102544 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication discrepancies detected
Number of subjects: 161
Study 38102544 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories of discrepancies
Number of subjects: 161
Study 38102544 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between discrepancies and comorbidities/drugs
Number of subjects: 161
Study 38102575 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 100
Study 38102575 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 38102639 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 0
Study 38102639 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 0
Study 38102647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anode over F3, cathode over F4, 5 sessions/week, 30 min/day, 2 mA stimulation intensity)
Number of subjects: 32
Study 38102647 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (identical protocol but with no electric stimulation)
Number of subjects: 32
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic variables and maternal characteristics assessed in the first year
Number of subjects: 0
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Children whose mothers were older and more satisfied with the TEDDY study
Number of subjects: 0
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Father participation
Number of subjects: 0
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Children whose mothers smoked
Number of subjects: 0
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Children whose mothers suffered from post-partum depression
Number of subjects: 0
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Children whose mothers were more anxious about their child's T1D risk
Number of subjects: 0
Study 38102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Father's study satisfaction
Number of subjects: 0